Semax: a Russian peptide with thin evidence and a new, temporary pharmacy status
Semax is a synthetic peptide of seven amino acids, built from a fragment of the stress hormone ACTH and developed in Russia. It is not an FDA-approved drug in the United States. As of November 10, 2026, a temporary federal policy lets licensed pharmacies prepare it for an individual patient. That is not a finding that it works or is safe, and this page explains what is and is not known.
Information current as of November 10, 2026. Educational only. Confirm everything here with your own clinician before starting, stopping or changing any medication.
At a glance
What it is
A synthetic heptapeptide, an analog of ACTH(4-10), developed in Russia.
Approval status
Not FDA-approved. Registered as a drug in Russia as nasal drops. A compounded product is not evaluated by FDA for safety, effectiveness or quality.
What the evidence shows
Small studies, mostly from a limited set of Russian groups, often in Russian-language journals. FDA reviewers found it insufficient for stroke, migraine or trigeminal neuralgia.
Main unknowns
No human pharmacokinetic studies and little safety reporting. FDA reviewers raised bleeding, immune-response and product-quality questions.
Pharmacy status
Covered by an interim federal enforcement discretion policy announced October 28, 2026. Formal rulemaking is still pending.
Sport
Not named on the 2026 WADA list. Athletes who are tested should check first.
What it is
What semax is
Semax is a heptapeptide, a chain of seven amino acids. It was designed as a stable analog of a short piece of ACTH, the pituitary hormone that signals the adrenal glands. Semax was developed by Russian researchers, and the FDA’s own review notes that it is a registered drug in Russia, sold there as 0.1% and 1% nasal drops.
It has no FDA approval for any use. It has no monograph in the United States, European or Japanese pharmacopoeias, and it is not a component of any FDA-approved drug. Online sellers market it for many goals, including memory, attention, anxiety, mood and recovery after stroke. None of those is an FDA-approved use.
Semax is not a hormone replacement and it is not a stimulant. It belongs with the other peptides some clinics now offer, such as oxytocin and GHK-Cu, where the human research is thin and the product quality matters.
How it is thought to work
What is known about its mechanism
The mechanism is poorly understood. In rodents, semax has been reported to change growth factors such as BDNF, genes for blood vessels and immune signaling, and serotonin pathways, and to show pain-relieving and anti-clotting effects. Most of this work is in animals and cells.
The FDA review also noted a finding that deserves attention. In mice, semax increased the dopamine release caused by amphetamine in a brain region tied to reward. The reviewers said that effect is typical of drugs with abuse potential and that no toxicity studies were available to settle the question. A mouse result does not show what happens in people.
Evidence
What the studies show
Most human studies of semax come from a limited set of Russian research groups and are published in Russian-language journals. Many are small and do not describe how patients were assigned or outcomes measured. Here is what the available reports show.
- Acute stroke, 1997. A report on 30 patients given semax with standard care, compared with 80 patients given standard care alone, described faster recovery of some neurological functions, especially movement. The abstract does not describe random assignment.
- After stroke, 2018. A study of 110 patients followed for five months compared groups with and without semax across early and late rehabilitation. Semax was linked to higher blood BDNF levels and a better Barthel index, a score of daily function. The groups were not blinded as described, and BDNF is a lab marker, not a patient outcome.
- Cerebrovascular insufficiency, 2005. A report on 187 patients described clinical improvement and fewer strokes and transient ischemic attacks. The abstract does not describe a comparison group.
- Migraine, 1996. FDA reviewers described a study of 12 people given a single intranasal dose. Four reported that the headache stopped, and the other eight had milder pain. There was no control group and no blinding.
The FDA’s staff reviewed semax for cerebral ischemia, migraine and trigeminal neuralgia. They found insufficient evidence of effectiveness for all three. They noted that only one meeting abstract supported use in cerebral ischemia, that the full text of several Russian papers was not available in English, and that the rest of the cited material came from animals, from healthy adults, or lacked detail on design and conduct.
Reports of benefit in memory or attention in healthy adults rest on very small studies, such as groups of about 14 people. Nothing here shows that semax improves thinking in healthy people or changes the course of any disease. Individual results vary, and trials in different populations are not directly comparable.
Safety
Safety unknowns
The honest summary is that the safety record is incomplete. FDA reviewers found no human pharmacokinetic studies, meaning no good data on how the body absorbs and clears it. Most of the studies they reviewed did not report side effects at all. Intranasal use was the only route described in the literature they found, and they found no safety data for injection.
Bleeding
One reference described possible anti-clotting properties. FDA reviewers raised concern for people with a bleeding risk or on drugs that raise it.
Immune response
Peptides can trigger antibodies, and can clump together. No studies looked at this for semax, and FDA reviewers said they could not rule it out.
Product quality
Semax is a common name, not a standard drug name. Different salts and forms are sold under it, and reviewers found little public data on impurities or endotoxin.
Who should not use semax, or should ask first
- Anyone who is pregnant, trying to conceive or breastfeeding, because there are no human safety data
- People with a bleeding disorder, or who take blood thinners or other drugs that raise bleeding risk
- People with a history of substance use disorder, mania or psychosis, or who take stimulant medications, because of the mouse dopamine finding and the lack of human data
- Children and teens, who are not treated through Summit
- Anyone who has had a serious allergic reaction to a peptide product
Call your physician for
- Hives, swelling of the face or lips, or trouble breathing
- Unusual bruising, nosebleeds that will not stop, or black stools
- New agitation, racing thoughts, or a severe change in sleep or mood
- Repeated nosebleeds or lasting irritation inside the nose
Sport
Semax and anti-doping rules
The World Anti-Doping Agency’s 2026 Prohibited List does not name semax. The list has a class for non-approved substances, which names other peptides as examples, and a class for corticotrophins, which names corticorelin and tetracosactide. WADA does not say where semax falls. Semax is registered in Russia, which may bear on the first class, and it is an ACTH analog, which may bear on the second.
If you compete in tested sport, get the answer from your anti-doping organization before you take anything. The list is updated every year.
Regulatory status
Semax and pharmacies, as of November 10, 2026
The timeline. On July 23 and 24, 2026, the FDA’s Pharmacy Compounding Advisory Committee met on several peptides. FDA review staff had proposed not adding semax to the 503A bulks list. They cited gaps in characterization and safety data, and insufficient evidence of effectiveness for the three uses reviewed. The committee, which is advisory only, voted in favor of adding semax. Press reports give the vote as 8 to 5 with one abstention.
On October 28, 2026, enforcement discretion was announced for six peptide bulk substances: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. The National Community Pharmacists Association reported it on October 29 as an FDA action. The Federal Register notice, titled Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, was filed on October 28 and published on October 30, 2026. It was issued by the Office of the Secretary of the U.S. Department of Health and Human Services, which oversees FDA, and it describes the policy as a draft. No timeframe was given.
What it means. Under this interim policy, federal officials do not intend to take enforcement action against a state-licensed pharmacy that prepares semax for an individual patient on a valid prescription and meets the policy’s conditions. The policy’s Appendix B lists semax as the free base, for intranasal use only. The policy sets no end date. It applies while the 503A bulks list is developed through rulemaking, and HHS says it may revisit it, for example if a safety signal or quality problem arises. It creates no rights and does not bind the government.
What it does not mean. Semax is not FDA-approved. FDA has not added it to the 503A bulks list, and formal rulemaking to do so is still pending. A compounded drug is not evaluated by FDA for safety, effectiveness or quality. The rules can change, and Dr. Miranda will tell you if they do.
Summit’s role
What Summit does with semax
Dr. Miranda decides whether semax fits you after your history and labs. If he considers it, a state-licensed pharmacy prepares it for you as a named patient. Summit does not dispense or sell it, and it keeps no stock in the office.
Nothing on this page promises a prescription. If semax does not fit, you will hear why, and the answer is often that the evidence does not support it for your goal. See pricing for what the program includes, including labs.
Common questions
Questions people ask
Is semax FDA-approved?
No. It is not an FDA-approved drug in the United States. It is registered as a drug in Russia. Under a temporary federal policy announced October 28, 2026, licensed pharmacies may prepare it for an individual patient under a prescription. The compounded product is not evaluated by FDA for safety, effectiveness or quality.
Did the FDA add semax to its approved compounding list?
No. Formal rulemaking to add it to the 503A bulks list is still pending. An advisory committee voted in favor in July 2026, but its vote is advisory, and FDA review staff had proposed not adding it.
Does semax work for stroke or memory?
The studies are small, mostly from a limited set of Russian groups, and FDA reviewers found the evidence insufficient for stroke, migraine and trigeminal neuralgia. There is no good evidence that it improves memory in healthy people. Individual results vary.
Is semax safe?
Not enough is known to say. FDA reviewers found no human pharmacokinetic studies, little reporting of side effects, and open questions about bleeding, immune response and product quality.
Can athletes use it?
Semax is not named on WADA’s 2026 Prohibited List, but WADA has not said how its broad classes apply to it. Tested athletes should ask their anti-doping organization first.
Will the rules change?
They may. The policy is interim and labeled a draft, and rulemaking is pending. Dr. Miranda will tell you if the status changes.
Sources
Where this comes from
All retrieved November 10, 2026.
- HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A and B. Federal Register FR Doc 2026-22192, October 30, 2026. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
- FDA. Briefing document for semax-related bulk drug substances, Pharmacy Compounding Advisory Committee, July 23-24, 2026. https://www.fda.gov/media/193348/download
- FDA. July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee: uses evaluated and meeting materials. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- U.S. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register notice, October 30, 2026 (91 FR 68526). https://www.federalregister.gov/d/2026-22192
- NCPA. FDA grants enforcement discretion to compounding six peptides. October 29, 2026. https://ncpa.org/newsroom/qam/2026/10/29/fda-grants-enforcement-discretion-compounding-six-peptides
- Gusev EI et al. Effectiveness of semax in acute period of hemispheric ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova 1997. https://pubmed.ncbi.nlm.nih.gov/11517472/
- Gusev EI et al. Efficacy of semax in patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova 2018. https://pubmed.ncbi.nlm.nih.gov/29798983/
- Gusev EI et al. Semax in patients with cerebrovascular insufficiency. Zh Nevrol Psikhiatr Im S S Korsakova 2005. https://pubmed.ncbi.nlm.nih.gov/15792140/
- World Anti-Doping Agency. Prohibited List (2026 list, effective January 1, 2026). https://www.wada-ama.org/en/prohibited-list
Confirm with your provider. This page is general education, not medical advice, and it does not diagnose or treat anything. Every medication carries risks and is not right for everyone. Medication is prescribed only after a physician evaluation determines it is appropriate for you. Individual results vary and no outcome is guaranteed. Information current as of November 10, 2026.
Next step
Start with a physician evaluation
Dr. Miranda reviews your history, medications and labs before any decision about semax.